Full Press Release Details
TAIPEI, Taiwan, Oct. 6, 2026 — YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES) and its affiliate EG BioMed Co., Ltd. have officially launched the AI Cancer Risk Assessment — an online tool that turns self-reported health information into a personalized risk report, available in both English and Chinese.
The Assessment covers ten cancer types: breast, colorectal, lung, head and neck, pancreatic, liver, endometrial, prostate, biliary tract, and gastric cancer. It takes approximately ten minutes to complete and requires no blood draw, imaging, or clinic visit.
Accessible Cancer Risk Awareness, Anytime
The AI Cancer Risk Assessment consists of 52 structured questions covering personal health history, lifestyle habits, and family background. Upon completion, users receive a personalized risk report that highlights their relative risk level across each of the ten cancer types covered by the tool.
The tool is available at mdi.eg-bio.com at a promotional price of $10 USD. It is designed as an educational awareness resource to encourage proactive health conversations — not as a substitute for clinical diagnosis or medical advice.
A Digital Bridge Between Awareness and Action
"Early awareness is the first step toward better outcomes. This tool is designed to lower the barrier to proactive health engagement — making it easier for individuals to understand their personal risk profile and take informed action," said Dr. Ethan Shen, Chairman and Chief Executive Officer of YD Bio.
The launch of the AI Cancer Risk Assessment reflects YD Bio's commitment to building accessible digital health touchpoints that complement the Company's broader oncology platform — including the DNA methylation–based liquid biopsy research conducted through EG BioMed's CLIA-certified, CAP-accredited laboratory in Bothell, Washington.
About EG BioMed
EG BioMed is a biotechnology and clinical services company focused on advancing early cancer detection and diagnostic solutions. YD Bio entered into a Memorandum of Understanding to merge with EG BioMed in January 2026 and is advancing the transaction, which is anticipated to close in 2026, subject to customary closing conditions, regulatory approvals, and the finalization of definitive agreements.
EG BioMed US is the U.S. clinical-laboratory subsidiary of EG BioMed and operates a CLIA-certified, CAP-accredited clinical laboratory in Bothell, Washington, focused on DNA methylation–based early cancer detection and AI-driven biomarker analytics. EG BioMed and EG BioMed US are affiliates of YD Bio.
About YD Bio Limited
YD Bio is a U.S.-anchored public biotechnology company building an integrated healthcare platform spanning regulated molecular diagnostics, clinical services, precision medicine, and life science commercialization. The Company operates DNA methylation–based oncology testing programs in the United States under a laboratory-developed test strategy and supports pharmaceutical and biotechnology partners through compliant life science distribution and clinical trial supply chain services. In addition, the Company maintains regulated ocular health commercialization operations and a consumer health distribution platform in Asia. For more information, visit ir.ydesgroup.com and follow the Company on Facebook , X , Threads , Instagram and LinkedIn .
Forward-looking statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions created by the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s plans, objectives and expectations for its business, strategy, operations, and certain on-going transactions, and the potential benefit of the Assessment and any synergies with its other oncology services. Forward-looking statements are not guarantees of future performance and can be identified by words such as “aim,” “intend,” “seek,” “believe,” “designed to,” “expects,” “anticipates,” “plans,” “may,” “could,” “will” and other similar expressions. Actual results may differ materially from those expressed or implied due to a variety of factors, including consumer demand and market acceptance; competition; regulatory and labeling requirements in Taiwan and other jurisdictions; currency exchange rates; geopolitical tensions and macroeconomic conditions; and other risks and uncertainties described in YD Bio’s filings with the U.S. Securities and Exchange Commission. The Company cautions investors not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update any forward-looking statement, except as required by law, and encourages investors to review the risk factors in its Annual Report on Form 20-F and other SEC filings.
For investor and media inquiries, please contact:
YD Bio Limited Investor Relations
Email: investor@ydesgroup.com
WFS Investor Relations Inc.
Email : services@wealthfsllc.com
Phone: +1 628 283 9214
Selected Media Coverage